The coronavirus pandemic has prompted a spike in the use of prescription medication for mental-health concerns, according to an analysis by Express Scripts Canada. The analysis found an 11 per cent increase in plan members making claims for antidepressants between January and June 2020, compared to the same period in 2019. As well, 61 per […]
As reported earlier this month, the Patented Medicine Prices Review Board has published a new draft of its guidelines and launched a 30-day written consultation period. While the law and regulations have already been passed, the implementation has been delayed from July 1, 2020 to Jan. 1, 2021. The new draft guidelines are in response […]
On May 12, Benefits Canada hosted a webinar to discuss the pharmaceutical industry’s efforts during the coronavirus crisis, as well as some key policy issues for Canadian insurers and their potential impact from the private-payer perspective. Since the end of April, 139 coronavirus treatments have been under investigation and Health Canada has approved several clinical trials […]
Manulife Financial Corp. is lending a hand to group benefits plan sponsors in light of the tight financial situation many businesses are in due to the coronavirus pandemic. The insurer is providing certain premium relief for all group benefits plan sponsors with an insured non-refund accounted benefits plan with Manulife. For the month of May, dental […]
The mental-health repercussions of the coronavirus could see global sales of psychiatric drugs increase to more than US$40 billion by 2025, according to data and analytics company GlobalData. Global sales for drugs to treat mental-health disorders such as depression, anxiety and obsessive compulsive disorder are expected to reach US$27.4 billion in 2020, an increase of US$717 […]
On March 3, the 2020 Employers Cancer Care Summit featured sessions on cancer-related issues and opportunities tied to benefits plans and the workplace. Many perspectives required when covering cancer drugs on benefits plans While treatment options for cancer are more than they used to be, many still aren’t covered under the public health-care system, according to Tim […]
Taking a look at private drug plans in 2020, a number of trends are converging: spending on specialty drugs is continuing its upward trajectory, advancements in a number of lifechanging therapies are in the pipeline and policy developments are coming at both the federal and provincial levels. In the face of this potential storm, plan […]
The Canadian Life and Health Insurance Association is asking the Patented Medicine Prices Review Board to include workplace-related factors when it sets maximum prices for medications. In its submission for the PMPRB’s consultation on its draft guidelines, which were released in November, the CLHIA said the life and health insurance industry is very supportive of the […]
The vast majority of pharmaceutical executives said they expect the incoming amendments to the Patented Medicine Prices Review Board to have a negative impact on their business plans in Canada, according to a new survey commissioned by Life Sciences Ontario. The survey, which drew on data from 46 respondents, including leaders from 36 Canadian and […]
While 2.7 million Canadians suffer from migraine, the condition can be subdivided based on its frequency, said Dr. Esma Dilli, neurologist and clinical assistant professor at the University of British Columbia, during Benefits Canada’s 2019 Vancouver Mental Health Summit on Dec. 12. Episodic migraine is defined by less than 15 headache days a month, whereas […]